Patents Assigned to AltruBio Inc.
  • Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers
    Patent number: 12290565
    Abstract: Provided herein are methods of treating or preventing a T-cell mediated inflammatory disease or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds to human PSGL-1 in combination with a Janus kinase (JAK) inhibitor. In some embodiments, the T-cell mediated inflammatory disease is GVHD, e.g., acute GVHD or chronic GVHD.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: May 6, 2025
    Assignee: AltruBio Inc.
    Inventors: Shih-Yao Lin, Feng-Lin Chiang, You-Chia Yeh
  • ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
    Publication number: 20240124604
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Application
    Filed: December 26, 2023
    Publication date: April 18, 2024
    Applicant: AltruBio Inc.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
  • Anti-PSGL-1 antibodies and uses thereof
    Patent number: 11897964
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: February 13, 2024
    Assignee: AltruBio Inc.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
  • METHODS OF USING ANTI-PSGL-1 ANTIBODIES IN COMBINATION WITH JAK INHIBITORS TO TREAT T-CELL MEDIATED INFLAMMATORY DISEASES OR CANCERS
    Publication number: 20230149544
    Abstract: Provided herein are methods of treating or preventing a T-cell mediated inflammatory disease or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds to human PSGL-1 in combination with a Janus kinase (JAK) inhibitor. In some embodiments, the T-cell mediated inflammatory disease is GVHD, e.g., acute GVHD or chronic GVHD.
    Type: Application
    Filed: November 16, 2022
    Publication date: May 18, 2023
    Applicant: AltruBio Inc.
    Inventors: Shih-Yao LIN, Feng-Lin CHIANG, You-Chia YEH
  • ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
    Publication number: 20210395383
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 23, 2021
    Applicant: AltruBio Inc.
    Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger